Characterization of source plasma from self‐identified vaccinated or convalescent donors during the 2009 H1N1 pandemic

Abstract

Targeted collection of plasma containing high levels of anti-influenza antibodies from self-identified donors was effective, but could be further improved by reducing the number of low-titer donations. More selective donor screening and/or testing for influenza antibodies could increase the potency of an influenza antibody-rich immune globulin (FLUIGIV).

The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection

“…Consistent with our finding, antibody titers in CCP units during the 2009 H1N1 pandemic were correlated with donor age, gender, or location with high virus frequency. Similar to our results, donors included in this study [16] had elevated nAb in younger convalescent donors and those who were older than 55 years. Some small case series suggested that male gender, older age, and hospitalization of patients with COVID-19 were consistently associated with increased antibody responses and worse COVID-19 outcome.…”

Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States

“…The use of convalescent serum/plasma for passive immunization has long been used to treat patients with emerging infectious diseases, including those with 1918 H1N1 pandemic influenza . More recently, convalescent plasma has been used to treat patients with 2009 H1N1 pandemic influenza and Middle East respiratory syndrome (MERS) in a pilot study . Both convalescent plasma and whole blood have been used as treatment in past EBOV outbreaks, though what role these products had in the recovery of patients is unclear, as a myriad of aggressive supportive measures were used in those cases.…”

Method for screening influenza neutralizing antibodies in crude human plasma and its derivatives using SPR

“…Utilizing some empiric rules to cut off low-antibody plasma, e.g. plasma samples inhibiting less than 25% or 30% of the HA antigen binding signal, the units enriched with specific antibodies may be efficiently selected for further processing into FluIGIV product with higher potency than previously achieved in the setting of donor self-identification [ 34 ]. As vaccines against newly emerged strains may be unavailable for many months after the start of a pandemic [ 29 ], high-potency IGIV infusions could be tested as a treatment for severe influenza disease, or to prevent severe disease in immunocompromised or other at-risk individuals with exposures or early symptoms [ 4 ].…”